Iryna Drozd ChromaDex ( NASDAQ: CDXC ) shares jumped 9% in early trading Friday after the company announced it had received FDA orphan drug designation and rare pediatric disease designation for its therapy candidate NRC in the treatment of ataxia telangiectasia. The company said plans were underway to file with the FDA to begin human clinical trials of the product. More on BioCardia, ChromaDex, etc.
Charles River Laboratories: Fair Valuation Against Fundamentals BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss' BioCardia intends to effect reverse stock split Collegium announces $35 million accelerated share repurchase program.
